Replying to @exosome
Have you tried Mensa? I made lifetime friends there; I can't say ever did that any place else. Mensans are all types of people. One guy was an engineer who manned a console at Cape Canaveral for Apollo 13, another was an eccentric dude whose wife worked at an adult book store😳😂. Mensa women are very relatable people too. It might be worth checking it out; you might make valuable contacts for your business too.
Replying to @PetsRescues
WELL, THE OVERTHROW IS IN PROGRESS !!!
🤔
Food additive rules and cancer drug approval standards are not the same thing. Comparing them to claim the FDA has “no high standard” is a category error.
The FDA rejected Summit Therapeutics’ application for ivonescimab (a PD-1/VEGF bispecific, originally developed in China and licensed by a Florida-based company) specifically because the global phase 3 HARMONi trial failed to show a statistically significant overall survival (OS) benefit. Median OS was 16.8 vs. 14.0 months (HR 0.79, 95% CI 0.62–1.01, p=0.057). The trial did meet its progression-free survival endpoint (HR 0.52, p<0.0001), but the FDA has stated that a PFS benefit without a statistically significant OS improvement does not support a positive benefit-risk profile in this setting. The agency had previously told the sponsor that proving patients live longer was required. This aligns with FDA guidance that treats OS as a gold-standard endpoint in oncology when feasible, because the goal is longer life, not just slower tumor growth.[]
On food: The EU is more precautionary on many additives, dyes, and certain pesticides (positive-list approach + precautionary principle), while the U.S. relies more on the GRAS pathway and post-market review. That is a real difference. However, it does not mean the FDA has uniformly “the weakest” food rules, nor does it erase the high evidentiary bar the agency applies to novel cancer therapies. Food regulation addresses chronic low-level exposures; oncology drugs are given to seriously ill patients and must clear rigorous efficacy and safety thresholds based on clinical trial data. The two are governed by different statutes, risk frameworks, and evidence standards.
The rejection here was driven by the trial results and the pre-specified OS requirement, not by the origin of the molecule or a general absence of standards.
Replying to @KMN34223 @GuntherEagleman






